Affigen, LLC

Affigen, LLC is a biotechnology company focused on the development and manufacture of innovative diagnostic and research reagents, specializing in antibody discovery and development for biomedical research applications. Founded in 2016 and headquartered in St. Louis, US, Affigen, LLC specializes in diagnostic and research reagents. The company underwent a significant funding round in February 2017, receiving USD 17.

00 mn in a Series A financing led by Black Beret Life Sciences. There are no mentions of subsidiaries or prior pivots in their business strategy. Affigen Inc. specializes in the manufacture and supply of diagnostic and research reagents, focusing on next-generation antibody discovery and development.

Core products include high-quality antibodies, ELISA kits, recombinant proteins, and assay kits for biomedical research. Their offerings cater to researchers and laboratories across the US, Canada, Europe, Australia, and Southeast Asia, ensuring compliance with ISO and GMP standards. Affigen generates revenue through direct sales of its product line, including flagship offerings such as the AffiAB® antibodies and AffiELISA® kits. They operate a B2B model, engaging primarily with research institutions and laboratories and facilitating transactions on a per-order basis.

Their pricing strategy allows for flexibility, with some items available at promotional rates. Affigen aims to leverage the USD 17. 00 mn raised in their Series A funding to support the development of new product lines and to enhance their market reach. The company plans to introduce advanced antibody products and expand into emerging markets in Southeast Asia and Europe by the end of 2024.

The funding will be instrumental in scaling their operations to meet the anticipated demand.